` 3692 (Hansoh Pharmaceutical Group Company Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

3692
vs
Hang Seng (Hong Kong)

Over the past 12 months, has outperformed Hang Seng (Hong Kong), delivering a return of 48% compared to the Hang Seng (Hong Kong)'s 30% growth.

Stocks Performance
3692 vs Hang Seng (Hong Kong)

Loading
3692
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com

Performance Gap
3692 vs Hang Seng (Hong Kong)

Loading

Over the past 12 months, has outperformed Hang Seng (Hong Kong) by 18.75%.

3692
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
3692 vs Hang Seng (Hong Kong)

Loading
3692
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
Hansoh Pharmaceutical Group Company Ltd vs Peers

Hang Seng (Hong Kong)
3692
LLY
JNJ
NOVO B
ROG
Add Stock

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
157B HKD
Industry
Pharmaceuticals

Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.

Intrinsic Value
18.8 HKD
Overvaluation 29%
Intrinsic Value
Price
H
Back to Top